Join Now

Glafabra Therapeutics Receives FDA Orphan Drug Designation for GT-GLA-S03, Advancing a Redosable Cell Therapy for Fabry Disease

By Natalie Themm | Published March 19, 2026

For Fabry patients, a potential path to converting 130 clinic visits into one treatment every five years.

Posted in BioUtah News | Tagged | Comments Off on Glafabra Therapeutics Receives FDA Orphan Drug Designation for GT-GLA-S03, Advancing a Redosable Cell Therapy for Fabry Disease

Glafabra Therapeutics, Uncommon Cures Collaborate to Advance Fabry Disease Therapy

By Natalie Themm | Published September 25, 2025

Glafabra Therapeutics, Uncommon Cures Collaborate to Advance Fabry Disease Therapy

Posted in BioUtah News | Tagged | Comments Off on Glafabra Therapeutics, Uncommon Cures Collaborate to Advance Fabry Disease Therapy

A Special Thanks To Our Legacy and Platinum Elite Members